Approval of the first biosimilar antibodies in Europe: A major landmark for the biopharmaceutical industry

In a defining moment for the European Medicines Agency (EMA) and the biopharmaceutical industry, on June 27, 2013 EMA’s Committee for Medicinal Products for Human Use adopted a positive opinion for two biosimilar infliximab products (Celltrion’s Remsima® and Hospira’s Inflectra®), and recommended th...

Descripción completa

Detalles Bibliográficos
Autores principales: Beck, Alain, Reichert, Janice M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851211/
https://www.ncbi.nlm.nih.gov/pubmed/23924791
http://dx.doi.org/10.4161/mabs.25864

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851211/
https://www.ncbi.nlm.nih.gov/pubmed/23924791
http://dx.doi.org/10.4161/mabs.25864

Ejemplares similares